Remdesivir in COVID-19: A Critical Review of Pharmacology, Pre-clinical and Clinical Studies
13 May, 2020 | 01:50h | UTC“While the first double-blind, randomized-controlled trial (DBRCT) found no significant benefit with remdesivir compared to placebo, preliminary reports from another DBRCT showed a significant faster recovery, without any difference in mortality.”